DE69726674T2 - Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren - Google Patents
Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren Download PDFInfo
- Publication number
- DE69726674T2 DE69726674T2 DE69726674T DE69726674T DE69726674T2 DE 69726674 T2 DE69726674 T2 DE 69726674T2 DE 69726674 T DE69726674 T DE 69726674T DE 69726674 T DE69726674 T DE 69726674T DE 69726674 T2 DE69726674 T2 DE 69726674T2
- Authority
- DE
- Germany
- Prior art keywords
- conjugates
- cell
- modulating
- elements
- specific binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 230000009870 specific binding Effects 0.000 title 1
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract 1
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract 1
- 102000018697 Membrane Proteins Human genes 0.000 abstract 1
- 108010052285 Membrane Proteins Proteins 0.000 abstract 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 abstract 1
- 125000003169 alpha-Gal epitope group Chemical group [C@H]1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)O[C@@H]1[C@H]([C@@H](O[C@@H]([C@@H]1O)CO)O[C@H]1[C@@H]([C@H](C(O[C@@H]1CO)*)NC(C)=O)O)O 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 239000012636 effector Substances 0.000 abstract 1
- 150000004676 glycans Chemical class 0.000 abstract 1
- 230000002779 inactivation Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001717 pathogenic effect Effects 0.000 abstract 1
- 229920001282 polysaccharide Polymers 0.000 abstract 1
- 239000005017 polysaccharide Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
- A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63038396A | 1996-04-10 | 1996-04-10 | |
| PCT/US1997/005842 WO1997037690A2 (en) | 1996-04-10 | 1997-04-09 | Cytomodulating conjugates of members of specific binding pairs |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69726674D1 DE69726674D1 (de) | 2004-01-22 |
| DE69726674T2 true DE69726674T2 (de) | 2004-10-21 |
Family
ID=24526956
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69726674T Expired - Fee Related DE69726674T2 (de) | 1996-04-10 | 1997-04-09 | Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20060002891A1 (de) |
| EP (1) | EP0833666B1 (de) |
| JP (1) | JPH10511989A (de) |
| AT (1) | ATE255910T1 (de) |
| AU (1) | AU2610097A (de) |
| CA (1) | CA2218737C (de) |
| DE (1) | DE69726674T2 (de) |
| ES (1) | ES2210514T3 (de) |
| WO (1) | WO1997037690A2 (de) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1027073A2 (de) * | 1996-11-19 | 2000-08-16 | Sangstat Medical Corporation | Verstärkter effekt für hapten-konjugierten haptenen |
| NZ504291A (en) * | 1997-11-10 | 2002-10-25 | Cytimmune Sciences Inc | Compositions and methods for targeted delivery of factors |
| WO2001032207A1 (en) * | 1998-10-30 | 2001-05-10 | United States Army Medical Research And Materiel Command | Methods for conferring active/passive immunotherapy |
| CA2328356A1 (en) | 1999-12-22 | 2001-06-22 | Itty Atcravi | Recreational vehicles |
| US7645743B2 (en) * | 1999-12-22 | 2010-01-12 | Altermune, Llc | Chemically programmable immunity |
| KR100863632B1 (ko) | 2000-03-31 | 2008-10-15 | 퍼듀 리서치 파운데이션 | 리간드-면역원 접합체를 사용한 치료 방법 |
| JP4868698B2 (ja) | 2001-05-02 | 2012-02-01 | パーデュー・リサーチ・ファウンデーション | マクロファージが仲介する疾患の治療および診断 |
| ES2338305T3 (es) * | 2001-09-28 | 2010-05-06 | Purdue Research Foundation | Metodo de tratamiento que utiliza conjugados ligando-inmunogeno. |
| CA2464472C (en) | 2001-10-22 | 2014-01-07 | The Scripps Research Institute | Antibody targeting compounds |
| US8043602B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| US8043603B2 (en) | 2002-02-07 | 2011-10-25 | Endocyte, Inc. | Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology |
| EP1629281B1 (de) | 2003-05-30 | 2008-10-29 | Purdue Research Foundation | Diagnoseverfahren für atherosklerose |
| EP2452695A3 (de) * | 2004-12-23 | 2013-01-23 | Purdue Research Foundation | Bildgebungsverfahren für Positronenemissionstomographie |
| EP1904183B1 (de) | 2005-07-05 | 2014-10-15 | Purdue Research Foundation | Pharmazeutische Zusammensetzung zur Behandlung von Arthrose |
| EP1940473A2 (de) | 2005-09-23 | 2008-07-09 | Purdue Research Foundation | Verfahren und vorrichtung für die multiphotonen-in-vivo-durchflusszytometrie |
| US8168164B2 (en) | 2006-02-03 | 2012-05-01 | Purdue Research Foundation | Targeted conjugates and radiation |
| US8685752B2 (en) | 2006-11-03 | 2014-04-01 | Purdue Research Foundation | Ex vivo flow cytometry method and device |
| JP5869205B2 (ja) | 2007-02-07 | 2016-02-24 | パーデュー・リサーチ・ファウンデーションＰｕｒｄｕｅ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | ポジトロン放射断層画像法 |
| EP2164525A2 (de) | 2007-05-25 | 2010-03-24 | Purdue Research Foundation | Verfahren zur darstellung von lokalisierten infektionen |
| KR101098581B1 (ko) * | 2009-01-09 | 2011-12-26 | 서울대학교산학협력단 | Ａｂｈ 항원을 이용한 염증질환 개선용 조성물 |
| EP2430033A4 (de) | 2009-05-05 | 2012-11-07 | Altermune Technologies Llc | Chemisch programmierbare immunität |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4314988A (en) * | 1979-10-31 | 1982-02-09 | Baker Instruments Corp. | Folic acid derivatives and process for preparation |
| JP2534222B2 (ja) * | 1982-05-12 | 1996-09-11 | プレジデント アンド フエロウズ オブ ハ−バ−ド カレツジ | 混成タンパク質生産用融合遺伝子 |
| US4681760A (en) * | 1985-04-17 | 1987-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Method of conferring immunotolerance to a specific antigen |
| US4676980A (en) * | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US4971792A (en) * | 1987-03-27 | 1990-11-20 | The Wistar Institute | Monoclonal antibodies against glycolipid antigens |
| US4946945A (en) * | 1987-06-23 | 1990-08-07 | Allergy Immuno Technologies, Inc. | Immunotherapy agents for treatment of IgE mediated allergies |
| ATE88900T1 (de) * | 1987-09-02 | 1993-05-15 | Ciba Geigy Ag | Konjugate von interferon alpha mit immunglobulinen. |
| DK8189A (da) * | 1988-01-12 | 1989-07-13 | Bunge Australia | Antigen-antistof-konjugater, deres fremstilling og anvendelse |
| KR900005995A (ko) * | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| DE68926380T2 (de) * | 1988-11-14 | 1996-09-12 | Kanegafuchi Chemical Ind | Sphärische Vinylchloridharzgranulate und Verfahren zu ihrer Herstellung |
| JPH04506662A (ja) * | 1989-07-14 | 1992-11-19 | アメリカン・サイアナミド・カンパニー | 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー |
| WO1991007418A1 (en) * | 1989-11-13 | 1991-05-30 | Xoma Corporation | Chimeric mouse-human a10 antibody with specificity to a human tumor cell antigen |
| CA2090105A1 (en) * | 1990-08-29 | 1992-03-01 | Jean-Paul Soulillou | Protein polyligands joined to a stable protein core |
| JP3105629B2 (ja) * | 1991-04-23 | 2000-11-06 | サングスタット メディカル コーポレイション | 特異的結合ペアのメンバーの細胞活性調節接合体 |
| US5547668A (en) * | 1995-05-05 | 1996-08-20 | The Board Of Trustees Of The University Of Illinois | Conjugates of folate anti-effector cell antibodies |
-
1997
- 1997-04-09 CA CA002218737A patent/CA2218737C/en not_active Expired - Fee Related
- 1997-04-09 AU AU26100/97A patent/AU2610097A/en not_active Abandoned
- 1997-04-09 AT AT97917902T patent/ATE255910T1/de not_active IP Right Cessation
- 1997-04-09 WO PCT/US1997/005842 patent/WO1997037690A2/en active IP Right Grant
- 1997-04-09 ES ES97917902T patent/ES2210514T3/es not_active Expired - Lifetime
- 1997-04-09 JP JP9536451A patent/JPH10511989A/ja not_active Ceased
- 1997-04-09 DE DE69726674T patent/DE69726674T2/de not_active Expired - Fee Related
- 1997-04-09 EP EP97917902A patent/EP0833666B1/de not_active Expired - Lifetime
-
2005
- 2005-09-13 US US11/180,409 patent/US20060002891A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| DE69726674D1 (de) | 2004-01-22 |
| EP0833666B1 (de) | 2003-12-10 |
| WO1997037690A3 (en) | 1998-03-05 |
| EP0833666A3 (de) | 1998-07-08 |
| US20060002891A1 (en) | 2006-01-05 |
| CA2218737A1 (en) | 1997-10-16 |
| EP0833666A2 (de) | 1998-04-08 |
| WO1997037690A2 (en) | 1997-10-16 |
| JPH10511989A (ja) | 1998-11-17 |
| ES2210514T3 (es) | 2004-07-01 |
| ATE255910T1 (de) | 2003-12-15 |
| AU2610097A (en) | 1997-10-29 |
| CA2218737C (en) | 2003-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0510949A3 (de) | Zytomodulierte Konjugate enthaltend spezifische Bindungspaargliedern | |
| DE69726674D1 (de) | Zellmodulierende konjugate aus elementen aus spezifischen bindungspaaren | |
| TR199900113A3 (tr) | Esnek hücreli malzeme, birlesimi ve hazirlanmasi için usul. | |
| ATE412432T1 (de) | Internalisierende erbb2 antikörper | |
| PT888384E (pt) | Polipeptido de fusao para influenciar as interaccoes entre proteinas | |
| PT983286E (pt) | Compostos de aminoalquil-glicosamina-fosfato e sua utilizacao como adjuvantes eimunoefectores | |
| MX9602879A (es) | Moleculas mutantes de ctla4 y usos de las mismas. | |
| DE3782394D1 (de) | Immobilisiertes, physiologisch aktives material. | |
| ATE186738T1 (de) | Kohlenhydratmodifizierte cytostatika | |
| ATE286139T1 (de) | Replikationskompetente anti-tumor vektoren | |
| AU6683900A (en) | Conjugate for mediating cell, compartment or membrane-specific transport of active substances | |
| MX9703702A (es) | Adhesivos mejorados de laminacion basados en isocianato. | |
| TR200003323T2 (tr) | Geniş-tesir sahalı mantar önleyiciler olarak suda eriyebilir azoller | |
| DE68904382D1 (de) | Schlagfesten kautschuk enthaltende schmelzklebstoffzusammensetzungen fuer die buchbinderei. | |
| YU12397A (en) | NOVEL PYRIMIDO [1,2-a] INDOLES | |
| WO2000003724A1 (fr) | Preparations pour immunotherapie anticancereuse comprenant un constituant somatique bacterien en tant qu'ingredient actif | |
| ATE444081T1 (de) | Proteine-abgabe durch polare epithelzellen schichte | |
| NO875262L (no) | Fremgangsmaate for aa komprimere kornformige formstoffer, spesielt stoepeformstoffer. | |
| DK0983361T3 (da) | Bakterielle pheromoner og anvendelser deraf | |
| NL1004478A1 (nl) | Transportrotor met snijinrichting voor een agrarische oogstmachine. | |
| ID27733A (id) | Metoksiminofenilasetamida | |
| DE58903624D1 (de) | Strahlenhaertende, thermoaktivierbare klebstoffmischungen. | |
| NO883886D0 (no) | Flammehemmende ethylencopolymermateriale. | |
| FI880795A0 (fi) | Banformat material, speciellt foer undertak. | |
| NO881932D0 (no) | Anordning for utmatning av korn- eller stykkeformet materiale. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8339 | Ceased/non-payment of the annual fee |